CANDACE LANKFORD: Open Payments
NPI 1134751530 · FRANKLIN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,553 in 80 payments from 13 companies in 2025. Trend: 2023 $1,769 · 2024 $1,575 · 2025 $1,553
Food & beverage: $1,553
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 20 | $420 |
| ABBVIE INC. | 18 | $282 |
| Otsuka America Pharmaceutical, Inc. | 11 | $220 |
| Janssen Pharmaceuticals, Inc | 7 | $181 |
| Supernus Pharmaceuticals, Inc. | 5 | $85 |
| Neurocrine BioSciences, Inc. | 4 | $82 |
| Alkermes, Inc. | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Teva Pharmaceuticals USA, Inc. | 3 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
Products named: COBENFY, VRAYLAR, REXULTI, INVEGA SUSTENNA, Qelbree, INGREZZA, ARISTADA, ABILIFY ASIMTUFII.
Industry payments across VA — which companies pay providers there.
